177 related articles for article (PubMed ID: 23134386)
1. The promise of antibody-drug conjugates.
Teicher BA; Doroshow JH
N Engl J Med; 2012 Nov; 367(19):1847-8. PubMed ID: 23134386
[No Abstract] [Full Text] [Related]
2. HER2-positive breast cancer: a new piece of the puzzle.
Gnant M; Bartsch R; Steger GG
Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817
[No Abstract] [Full Text] [Related]
3. Ado-trastuzumab emtansine approved for advanced breast cancer.
Traynor K
Am J Health Syst Pharm; 2013 Apr; 70(7):562. PubMed ID: 23515502
[No Abstract] [Full Text] [Related]
4. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
Cho WC; Roukos DH
Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
[No Abstract] [Full Text] [Related]
5. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
[No Abstract] [Full Text] [Related]
6. [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].
Noguchi E; Shimizu C
Gan To Kagaku Ryoho; 2013 Jan; 40(1):10-4. PubMed ID: 23306913
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies: TH3RESA trial, overcoming hurdles in breast cancer.
Villanueva MT
Nat Rev Clin Oncol; 2014 Jul; 11(7):379. PubMed ID: 24913372
[No Abstract] [Full Text] [Related]
8. Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.
de Vries CL; Linn SC; Brandsma D
J Neurooncol; 2016 Apr; 127(2):401-3. PubMed ID: 26732082
[No Abstract] [Full Text] [Related]
9. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer brain metastases responding to primary systemic therapy with T-DM1.
Bartsch R; Berghoff AS; Preusser M
J Neurooncol; 2014 Jan; 116(1):205-6. PubMed ID: 24065570
[No Abstract] [Full Text] [Related]
11. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.
Isakoff SJ; Baselga J
J Clin Oncol; 2011 Feb; 29(4):351-4. PubMed ID: 21172881
[No Abstract] [Full Text] [Related]
12. Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
Géraud A; Xu HP; Beuzeboc P; Kirova YM
Cancer Radiother; 2016 Jun; 20(4):312-3. PubMed ID: 27342941
[No Abstract] [Full Text] [Related]
13. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
Med Lett Drugs Ther; 2013 Sep; 55(1424):75-6. PubMed ID: 24043217
[No Abstract] [Full Text] [Related]
14. [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].
Frenel JS; Bally O; Bourbouloux E; Berton-Rigaud D; Campone M; Bachelot T; Heudel PÉ
Bull Cancer; 2016 May; 103(5):507-10. PubMed ID: 26992855
[No Abstract] [Full Text] [Related]
15. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
Haddley K
Drugs Today (Barc); 2013 Nov; 49(11):701-15. PubMed ID: 24308017
[TBL] [Abstract][Full Text] [Related]
16. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Hurvitz SA; Dirix L; Kocsis J; Bianchi GV; Lu J; Vinholes J; Guardino E; Song C; Tong B; Ng V; Chu YW; Perez EA
J Clin Oncol; 2013 Mar; 31(9):1157-63. PubMed ID: 23382472
[TBL] [Abstract][Full Text] [Related]
17. [New Hope for HER2-Positive Metastatic Breast Cancer Treatment: Trastuzumab Emtansine (T-DM1) From the Perspective of Nursing Care].
Kuo HH; Chen WW
Hu Li Za Zhi; 2016 Oct; 63(5):121-126. PubMed ID: 27699747
[TBL] [Abstract][Full Text] [Related]
18. T-DM1 Extends Survival in HER2+ Breast Cancer.
Cancer Discov; 2016 Feb; 6(2):OF4. PubMed ID: 26676162
[TBL] [Abstract][Full Text] [Related]
19. From linear 'dogma' and trastuzumab-emtansine to future transcriptional circuitry-based drug discovery for breast cancer.
Lianos GD; Roukos DH
Future Oncol; 2014 Feb; 10(2):145-8. PubMed ID: 24490597
[No Abstract] [Full Text] [Related]
20. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
